Document is current

Any future updates will be listed below

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Crossref DOI link: https://doi.org/10.1186/s12885-022-10455-0

Published Online: 2022-12-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark